Idorsia
EU regulator backs Idorsia’s Quviviq for adults with insomnia
Joy Persaud
CHMP, EU, Idorsia, insomnia, market access, MHRA, pharma
0 Comment
X
EU regulator backs Idorsia’s Quviviq for adults with insomnia
https://pharmaphorum.com/news/eu-regulator-backs-idorsias-quviviq-for-adults-with-insomnia/
Dream result for Idorsia as FDA clears its insomnia drug
Phil Taylor
Belsomra, Dayvigo, Eisai, Idorsia, insomnia, Merck & Co, Quviviq, regulatory approval
0 Comment
X
Dream result for Idorsia as FDA clears its insomnia drug
https://pharmaphorum.com/news/dream-result-for-idorsia-as-fda-clears-its-insomnia-drug/
Idorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial win
Richard Staines
Eisai, Idorsia, insomnia, Merck & Co, neurology, R&D
0 Comment
X
Idorsia on course to take on Eisai and Merck & Co after latest insomnia phase 3 trial win
https://pharmaphorum.com/news/idorsia-on-course-to-take-on-eisai-and-merck-co-after-latest-insomnia-phase-3-trial-win/
Neurocrine signs $400M-plus deal with Idorsia for epilepsy drug
Phil Taylor
central nervous system, epilepsy, Idorsia, licensing, Neurocrine Biosciences, neurology
0 Comment
X
Neurocrine signs $400M-plus deal with Idorsia for epilepsy drug
https://pharmaphorum.com/news/neurocrine-signs-400m-plus-deal-with-idorsia-for-epilepsy-drug/